|
GOSR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.98659977357352E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.42289996136236E-09 |
| Normal-vs-Stage2 |
3.019400E-03 |
| Normal-vs-Stage3 |
3.06780045811195E-10 |
| Normal-vs-Stage4 |
5.64750002318704E-09 |
| Stage1-vs-Stage2 |
1.379430E-01 |
| Stage1-vs-Stage3 |
1.265620E-01 |
| Stage1-vs-Stage4 |
7.114200E-02 |
| Stage2-vs-Stage3 |
1.669790E-02 |
| Stage2-vs-Stage4 |
1.714450E-02 |
| Stage3-vs-Stage4 |
6.908800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.07009989547669E-11 |
| Normal-vs-AfricanAmerican |
9.941200E-03 |
| Normal-vs-Asian |
2.6448000001178E-07 |
| Caucasian-vs-AfricanAmerican |
1.300980E-01 |
| Caucasian-vs-Asian |
6.996000E-01 |
| AfricanAmerican-vs-Asian |
1.135240E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.08239994744963E-09 |
| Normal-vs-Female |
2.6429000099526E-09 |
| Male-vs-Female |
2.732000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.22650000342762E-08 |
| Normal-vs-Age(41-60Yrs) |
7.88370002613448E-09 |
| Normal-vs-Age(61-80Yrs) |
8.67740002075124E-09 |
| Normal-vs-Age(81-100Yrs) |
5.081900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.045200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.951000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.937600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.445400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.556000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.951200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.320500E-03 |
| Classical-VS-Follicular |
3.779000E-01 |
| Classical-VS-Other |
1.200630E-01 |
| Classical-VS-Normal |
2.67239996798452E-09 |
| Tall-VS-Follicular |
3.239800E-03 |
| Tall-VS-Other |
6.694200E-01 |
| Tall-VS-Normal |
1.52250001494991E-09 |
| Follicular-VS-Other |
1.222040E-01 |
| Follicular-VS-Normal |
1.789830E-04 |
| Other-VS-Normal |
7.752500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.82940000002108E-08 |
| Normal-vs-N1 |
1.53389999590914E-08 |
| N0-vs-N1 |
5.952300E-02 |
|
|
